How Has the Spinal Muscular Atrophy Market Evolved Historically and What is its Current Size
The spinal muscular atrophy market has seen considerable growth due to a variety of factors.
• The market size for spinal muscular atrophy has experienced a speedy expansion of late. It is set to rise from $3.53 billion in 2024 to $4.01 billion in 2025, yielding a compound annual growth rate (CAGR) of 13.5%.
The growth observed in the historic period can be linked to better early detection and diagnosis, a rise in rare genetic disease prevalence, enhancements in healthcare infrastructure, support from the government and regulatory bodies, and a surge in healthcare needs that are yet to be met.
What is the Forecasted Market Size and CAGR for the Spinal Muscular Atrophy Market?
The spinal muscular atrophy market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for spinal muscular atrophy is projected to experience a swift expansion in the coming years. The market is predicted to reach $6.59 billion by 2029, with a compound annual growth rate (CAGR) of 13.2%.
This anticipated growth over the forecast period can be credited to factors such as an increase in awareness and diagnosis, broader access to treatment, the rise in healthcare investments towards rare diseases, conducive regulatory conditions, and escalating healthcare expenditure. Key trends that are expected to steer the market over the forecast period encompass progress in oral therapies, embracing gene therapy, technological progress in drug delivery systems, the inclusion of artificial intelligence in the development of SMA treatments, and gene editing technologies.
What Key Factors and Trends are Driving the Growth of the Spinal Muscular Atrophy Market?
The growth of the spinal muscular atrophy market is anticipated to be driven by the increasing occurrence of rare genetic diseases. These diseases, which are caused by gene mutations, affect a small portion of the population and typically lead to severe, lasting health issues. The escalating incidence of these rare genetic conditions can be attributed to advances in diagnostic technologies, heightened awareness, and improved genetic testing access. This leads to a higher identification and reporting rate. Spinal muscular atrophy (SMA) serves as an ideal example of the complex issues and potential in comprehending inherited disorders, emphasizing the need for continued research in genetic conditions. A report from the Office for National Statistics, a UK government department, noted in July 2023 that genetic testing of SMN1 has facilitated precise epidemiological studies. This revealed that SMA affects 1 in every 10,000 to 20,000 live births, with over 95% of the afflicted patients displaying homozygous deletion for SMN1. Hence, the escalating occurrence of rare genetic disorders is expected to push the growth of the spinal muscular atrophy market.
What Are The Principal Market Segments In The Global Spinal Muscular Atrophy Healthcare Industry?
The spinal muscular atrophy market covered in this report is segmented –
1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)
2) By Age: Pediatric, Adults
3) By Treatment: Drug Therapy, Gene Therapy
4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy
Subsegments:
1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA
2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA
3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA
4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA
Pre-Book The Spinal Muscular Atrophy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Spinal Muscular Atrophy Market?
Leading industry players in the spinal muscular atrophy market are pushing the envelope by creating cutting-edge products like dry syrup to enhance medicine compliance and simplify the administration process for children and other patient groups who struggle with swallowing. Dry syrup is essentially a powdered form of a drug, which is mixed with water before being consumed. It's mostly recommended for children and patients who find it hard to swallow tablets or capsules. For example, in September 2024, Japan's Chugai Pharmaceutical Co., Ltd. received regulatory approval from the Ministry of Health, Labour and Welfare to expand the use of its drug Evrysdi (risdiplam) to include pre-symptomatic spinal muscular atrophy (SMA), even in babies under two months of age. This development is pivotal because it can potentially improve treatment outcomes by starting the medication before symptoms manifest. The RAINBOWFISH study, which evaluated the safety and effectiveness of Evrysdi in infants diagnosed with SMA but yet to display symptoms, backed this decision. According to the study's results, infants treated with the drug reached mobility milestones, such as sitting without support and enhanced motor skills, within 12 months. These findings highlight the potential of the drug to alter the course of the disease if administered early.
Who Are the Key Players in the Spinal Muscular Atrophy Market?
Major companies operating in the spinal muscular atrophy market are include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Bayer AG
• Novartis AG
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• Genentech Inc.
• PTC Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• Biohaven Ltd.
• Catalyst Pharmaceuticals Inc.
• RegenXBio Inc.
• Cytokinetics Inc.
• AveXis Inc.
• Scholar Rock Inc.
• Genethon
• CANbridge Pharmaceuticals Inc.
• NMD Pharma A/S
• Hanugen Therapeutics Inc.
• Beijing Jinlan Gene Technology Co. Ltd.
What are the Regional Insights into the Spinal Muscular Atrophy Market?
North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
